On May 20, 2022, Novavax announced the submission of a request to the European Medicines Agency to expand the conditional marketing authorization (CMA) of Nuvaxovidﾙ (NVX-CoV2373) COVID-19 vaccine in the European Union (EU) as a homologous and heterologous booster dose for individuals aged 18 and over.